💰 Larger firms are hesitant to switch from traditional systems due to regulations. In contrast, smaller companies favor modern solutions.
🤝 The key lies in convincing clients of technology benefits. Successful adoption can ease financial burdens and integrate existing systems effectively.
🔍 Innovations like AI offer promising solutions, addressing challenges in protein therapeutic production.
Introduction:
The article discusses the challenges that Contract Development and Manufacturing Organizations (CDMOs) face in convincing their clients to adopt new bioprocessing technologies. Despite a willingness to invest in innovative systems, CDMOs must navigate economic justifications and regulatory hurdles while demonstrating the tangible benefits of modern technologies to their customers.
- CDMOs recognize the value of multi-use platforms for bioprocessing but find bespoke systems harder to justify economically.
- The adoption of new technologies in biopharma varies based on company size and product established, with larger firms often hesitant to switch from traditional systems.
- Investing in innovative technologies poses significant upfront costs, including equipment, infrastructure, and personnel training for CDMOs.
- The ability to demonstrate specific benefits of new technologies is crucial for CDMOs to persuade clients to bear additional costs.
- Technologies perceived to save time and money, such as artificial intelligence in protein engineering, have greater potential for acceptance among clients.
Conclusion:
In summary, CDMOs are strategically considering their investments in bioprocessing technologies, balancing costs, regulatory implications, and client needs. Future advancements that demonstrate cost-effectiveness and problem-solving capabilities are likely to facilitate wider adoption of these new technologies in the biopharma sector.
